PapersPMID:27340676
Silymarin in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
What moved
1 findingHow to read these marks →- Decreases fasting blood glucose
moderate
“Silymarin administration was associated with a significant reduction in fasting blood glucose levels (mean difference [MD] (−26.86 mg/dL; 95% CI [−35.42, −18.30])) in four trials.”
- Study
- meta-analysis
- Effect
- −26.86 mean difference, 95% CI −35.42 to −18.3
- Dose studied
- silymarin 200 to 600 mg daily across the included trials
- Population
- Patients with type 2 diabetes mellitus; four pooled randomised controlled trials
Study record
- Design
- meta-analysis
- Species
- human
- Population
- Patients with type 2 diabetes mellitus (five randomized controlled trials)
- Participants
- 270
- Comparator
- not stated in the paper / placebo
- Duration
- not reported
- Endpoints measured
- 4